Bone Biologics (US:BBLG) Globenewswire·2026-01-08 13:00Core Insights - Bone Biologics Corporation achieved significant milestones in 2025, including the extension of rhNELL-1 shelf life, advancement of NB1 development, and a strengthened balance sheet while maintaining compliance with Nasdaq [1][2][5] 2025 Highlights - The company focused on strategic priorities across development, operations, and corporate governance to support ongoing programs and maintain organizational stability [3] - Key accomplishments included extending the validated shelf life of rhNELL-1 to 24 months, completing a public offering for gross proceeds of $5 million, and filing a U.S. patent application related to bone regeneration technology [5] - The company regained compliance with Nasdaq's minimum bid price requirement in June 2025, enhancing access to public capital markets [5] - Management increased investor engagement through participation in conferences and communication of progress in clinical and operational initiatives [5] Outlook for 2026 - The company plans to continue advancing its clinical-stage program and strengthening its operational foundation in 2026 [4] - Focus areas include the ongoing development of NB1, regulatory readiness, and commercialization planning [5] - The company aims to maintain prudent capital management while supporting scientific progress and shareholder engagement [5]